The estimated Net Worth of Fred E Cohen is at least $2.23 Milion dollars as of 20 January 2021. Frederick Cohen owns over 20,000 units of Intellia Therapeutics Inc stock worth over $607,200 and over the last 19 years he sold NTLA stock worth over $1,074,400. In addition, he makes $548,631 as Independent Director at Intellia Therapeutics Inc.
Frederick has made over 20 trades of the Intellia Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of NTLA stock worth $275,600 on 20 January 2021.
The largest trade he's ever made was exercising 100,000 units of Intellia Therapeutics Inc stock on 8 January 2015 worth over $129,000. On average, Frederick trades about 2,658 units every 19 days since 2005. As of 20 January 2021 he still owns at least 30,000 units of Intellia Therapeutics Inc stock.
You can see the complete history of Frederick Cohen stock trades at the bottom of the page.
Dr. Frederick E. Cohen Ph.D. M.D.. M.P.H., is Independent Director of the Company since January 2019. Dr. Cohen co-founded Vida Ventures, a biotechnology venture capital fund, in 2017 and has served as one of its senior managing directors since then. From 2001 to 2016, he was a partner of TPG, a private equity company, and served as the co-head of its biotechnology group, TPG Biotech, a venture capital fund that he founded in 2001. Dr. Cohen currently serves as a senior advisor to TPG. From 1988 through December 2014, Dr. Cohen was a professor of cellular and molecular pharmacology at the University of California, San Francisco, where he also held various clinical responsibilities, including as a research scientist, an internist for hospitalized patients, a consulting endocrinologist, and chief of the division of endocrinology and metabolism. Dr. Cohen currently serves on the boards of directors of Progyny, Inc., CareDx, Inc., UroGen Pharma Ltd., and Veracyte, Inc. Within the last five years, Dr. Cohen has also served on the boards of directors of the following public biotechnology and pharmaceutical companies: Genomics Health, Inc. (until November 2019), Tandem Diabetes Care, Inc. (until June 2019), BioCryst Pharmaceuticals, Inc. (until January 2019), Five Prime Therapeutics, Inc. (until May 2018), and Roka Bio Science (until its acquisition in October 2017) and Quintiles Transnational Holdings Inc. (now IQVIA Holdings Inc.) (until November 2015). Dr. Cohen was a co-founder and executive chairperson of privately held Cell Design Labs, which was acquired by Gilead Sciences, Inc. (“Gilead”) in December 2017. He holds a B.S. in molecular biophysics and biochemistry from Yale University, a D.Phil. in molecular biophysics from Oxford University and an M.D. from Stanford University. Dr. Cohen completed his postdoctoral training and postgraduate medical training in internal medicine and endocrinology at the University of California, San Francisco.
As the Independent Director of Intellia Therapeutics Inc, the total compensation of Frederick Cohen at Intellia Therapeutics Inc is $548,631. There are 8 executives at Intellia Therapeutics Inc getting paid more, with Laura Sepp-Lorenzino having the highest compensation of $1,762,490.
Fred's mailing address filed with the SEC is 400 ALEXANDER PARK DRIVE, , PRINCETON, NJ, 08540.
Over the last 9 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela a Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: